Drugs / IVX-A12
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06481579 | Jun → Jul 2024 | — | Icosavax, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05903183 | May → Jun 2023 | — | Icosavax, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IVX-A12 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05903183 ↗ |
| Modality | Vaccine | “Respiratory Syncytial Virus and Human Metapneumovirus Bivalent Combination Virus-like Particle Protein Subunit Vaccine” NCT05903183 ↗ |
| Route | Intramuscular | “a single intramuscular (IM) dose of IVX-A12” NCT05903183 ↗ |